Pioglitazone HCl is a selective peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist, used to treat diabetes.
J Cell Mol Med. 2020 Jun;24(12):6833-6845.
Seizure-induced impairment in neuronal ketogenesis: Role of zinc-α2-glycoprotein in mitochondria
Pioglitazone HCl purchased from AbMole
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||69 mg/mL in DMSO|
Effect of pioglitazone medication on the incidence of dementia.
Heneka MT, et al. Ann Neurol. 2015 Aug;78(2):284-94. PMID: 25974006.
|Related PPAR Products|
LY518674 is a potent and selective PPAR-alpha antagonist with EC50 of 42 nM for human PPARα.
Pemafibrate is a potent and highly specific PPARα agonist, with EC50s of 1 nM, 1.10 μM and 1.58 μM for h-PPARα, h-PPARγ and h-PPARδ, respectively.
Seladelpar (MBX-8025; RWJ-800025) is a selective peroxisome proliferator-activated receptor (SPPAR) -δ receptor agonist.
EHP-101 (VCE-004.8) is an orally active, specific PPARγ and CB2 receptor dual agonist.
Lanifibranor (IVA-337) is a peroxisome proliferator-activated receptors (PPAR) agonist, with EC50s of 1.5, 0.87 and 0.21 μM for human PPARα, PPARσ and PPARγ, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.